Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antibacterial Agents
Pharma company reports results of aminomethylcyclines trial
August 26th, 2005
Paratek Pharmaceuticals, Inc., announced that the company is conducting a phase I clinical trial of its lead compound from a new class of antibiotics called aminomethylcyclines (AMCs), derived from the well-known tetracycline family. PTK 0796 is a novel, broad-spectrum antibiotic that has been shown to be highly effective in animal models at treating clinically prevalent infections caused by Gram-positive, Gram-negative, atypical and anaerobic bacteria, including those with multi-drug resistance. The compound is the first in the AMC class to enter clinical development. Thomas J. Bigger, president and CEO of Paratek Pharmaceuticals, stated, "This is...
Source: Drug Week (2005-08-26)
|
